No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs

Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294-3360, USA.
International Journal of Obesity (Impact Factor: 5). 07/2007; 31(6):1014-22. DOI: 10.1038/sj.ijo.0803533
Source: PubMed


Atypical antipsychotic drugs (AAD) induce significant weight gain in female C57BL/6J mice. The effect of dietary fat on weight gain and serum lipids in this model is unknown.
Test the hypothesis that the obesigenic effects of these drugs are greater in the presence of a high-fat diet.
Female C57BL/6J mice were treated with atypical antipsychotics for 3 weeks and fed either a low-fat or high-fat diet (4.6 vs 15.6% fat by wt). Food intake (FI), body weight (BW), body composition, and serum lipids were measured during treatment with optimized doses of olanzapine, quetiapine, and risperidone. Energy intake (EI) and feed efficiency (FE) were calculated. Group differences in change were analyzed via repeated measures analysis of variance (ANOVA). Serum lipid concentrations, EI and FE were compared using two-way ANOVA.
AAD-treated mice gained significantly more weight than controls after 3 weeks (P<0.001). Treatment and diet had significant effects on FI and EI over time (P<0.001). AAD-treated mice had significantly higher FE than controls (P<0.05); however, there was no significant drug by diet interaction (P=0.65). Risperidone low-fat mice gained significantly more absolute fat mass than placebo low-fat mice (P<0.05). All treatment groups, except quetiapine low-fat and olanzapine high-fat, gained significantly more absolute lean mass than placebo controls (P<0.05). Cholesterol levels were significantly lower in quetiapine and risperidone than placebo (P<0.05). Risperidone low-fat mice had significantly higher triglyceride levels than placebo and risperidone high-fat mice (P<0.05).
A high-fat diet does not increase AAD-induced BW gain in female mice during a 3-week treatment period.

Download full-text


Available from: Patricia Jumbo-Lucioni,
  • Source
    • "Similar results were observed in female Wistar rats, hooded-Lister rats, and CD-1 mice (2, 3, 12). However, our previous study in mice found olanzapine and risperidone induced a significant increase in lean mass, but not fat mass (22). The potential explanation was based on the age of the mice, as overfeeding young animals leads to an increase of lean mass, accounting for 80% of weight gain relative to adults, whose lean mass comprised only 15-30% of weight gain (22, 25, 26). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective To investigate the effect of risperidone on energy expenditure and weight gain in female C57BL/6J mice. Design and Methods Body weight and composition, food intake, energy expenditure, and activity were determined weekly. mRNA expression of uncoupling protein 1 in brown adipose tissue, orexin and brain-derived neurotrophic factor in the hypothalamus were quantified by Real-Time PCR. Results Risperidone tended to induce a greater body weight gain (P=0.052) and significantly higher food intake (P=0.038) relative to the placebo-treated group. Risperidone-treated mice had a higher resting energy expenditure (P=0.001), and total energy expenditure (P=0.005) than the placebo group. There were no effects of treatment, time, and treatment by time on NREE between groups. Risperidone-treated mice showed a significantly lesser locomotor activity than placebo-treated mice over 3 weeks (P<0.001). Risperidone induced a higher UCP1 mRNA (P=0.003) and a lower orexin mRNA (P=0.001) than placebo. Discussion Risperidone-induced weight gain is associated with hyperphagia and a reduction in locomotor activity in C57BL/6J mice. Additionally, higher total and resting energy expenditure were accompanied by higher levels of UCP1 mRNA in BAT. The increased total energy expenditure could not offset the total intake of energy through risperidone-induced hyperphagia, therefore resulting in weight gain in female C57BL/6J mice.
    Obesity 05/2013; 21(9). DOI:10.1002/oby.20350 · 3.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antipsychotic drugs (APDs), and the 'atypical' APDs in particular, are commonly associated with metabolic side effects in humans. These include glucose dysregulation, insulin resistance, hyperlipidemia, weight gain and hypertension, which put patients at increased risk of cardiometabolic disorders. The underlying biology of APD-induced side effects in humans is poorly understood, and therefore preclinical rodent models are essential for translational research. With numerous recent studies on the topic, there is an emerging consensus that some symptoms, such as glucose dysregulation and insulin resistance, are more reliably observed than others, such as weight gain and hypertension, but, comparison between preclinical studies is complicated by numerous factors, including drug-specific effects and variables such as diet and treatment regimen. In this paper, we provide a major review of this important and growing field of preclinical study, and address crucial issues for future research.
    Trends in Pharmacological Sciences 10/2010; 31(10):484-97. DOI:10.1016/ · 11.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although nearly all atypical antipsychotic drugs (AAPDs) of second- generation are associated with body weight gain in adults with prolonged exposure; but reports on third-generation AAPDs like Aripiprazole (ARI) and weight gain are scanty and ambiguous. This may be due to unique mechanism of action. This study is undertaken to investigate the effect of gestational exposure to equivalent therapeutic doses of ARI on maternal and fetal weight gain; and its long-lasting impact on postnatal development and growth of offspring in rodent model. 30 pregnant Wistar rats were exposed to selected doses (2mg, 3mg and 5mg/kg BW) of ARI from GD3-21 orally with control subjects. Half of the pregnant subjects of each group were sacrificed at GD22 and rests of the rats were allowed to deliver normally and pups were reared postnatally up to 10 weeks of age. In ARI treated groups, there was no substantial alteration of body weight gain and food intake in pregnant subjects while significant reduction was found in fetal and postnatal (pre-and post weaning) body weight gain. ARI was found to be neutral for substantial weight gain in pregnant rats but may induce significant weight loss in fetuses and may create long-lasting negative impact on offspring growth (in weight) till PND70. Therefore, ARI could be an alternative of second- generation AAPDs for adult females but may not be safe for developing fetuses and offspring.
    10/2013; 9(1). DOI:10.2174/15748863113086660061